In cohort A (comprising patients with mesothelioma, uveal melanoma, renal cell carcinoma, cholangiocarcinoma), 9 patients demonstrated tumor response (1 partial response, 8 stable disease), out of which 7 had a BAP1 mutation. This evidence concerns the gene BAP1 and cholangiocarcinoma.